Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial

被引：1

作者：

Gratzke, C. J. ^{[1
]}

Fizazi, K. ^{[2
]}

Shore, N. D. ^{[3
]}

Smith, M. R. ^{[4
,5
]}

Feyerabend, S. ^{[6
]}

Grabbert, M. ^{[1
]}

Carles, J. ^{[7
]}

Lebret, T. ^{[8
]}

Vjaters, E. ^{[9
]}

Werbrouck, P. ^{[10
]}

Miskic, M. ^{[11
]}

Ortiz, J. ^{[12
]}

Schmall, A. ^{[13
]}

Le Berre, M. A. ^{[14
]}

Verholen, F. ^{[15
]}

机构：

[1] Univ Hosp Freiburg, Urol, Freiburg, Germany

[2] Inst Gustave Roussy, Canc Med Dept, Villejuif, France

[3] Carolina Urol Res Ctr, Dept Urol, Myrtle Beach, SC USA

[4] Massachusetts Gen Hosp, Urol Oncol, Boston, MA 02114 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Studienpraxis Urol, Nurtingen, Germany

[7] Vall Hebron Univ Hosp, Genitourinary Oncol, Barcelona, Spain

[8] Hop Foch, Urol, Suresnes, France

[9] P Stradins Clin Univ Hosp, Urol, Riga, Latvia

[10] AZ Groeninge, Urol, Kortrijk, Belgium

[11] Bayer Consumer Care AG, Basel, Switzerland

[12] Bayer Healthcare, Whippany, NJ USA

[13] Bayer AG, Med Advisor Oncol, Berlin, Germany

[14] Bayer Healthcare SAS, Biostat, Loos, France

[15] Bayer Consumer Care AG, GU Franchise, Basel, Switzerland

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

630P

引用

页码：S664 / S664

页数：1

共 50 条

[1] Time Course Profile of Adverse Events of Interest and Serious Adverse Events With Darolutamide in the ARAMIS Trial
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 13 - 14
[2] Time Course Profile of Adverse Events of Interest and Serious Adverse Events With Darolutamide in the ARAMIS Trial
Grabbert, Markus
Gratzke, Christian
Fizazi, Karim
Shore, Neal
Smith, Matthew
Feyerabend, Susan
Carles, Joan
Lebret, Thierry
Vjaters, Egils
Werbrouck, Patrick
Miskic, Marina
Schmall, Anja
Le Berre, Marie Aude
Borghesi, Gustavo
Verholen, Frank
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 105 - 105
[3] SURVEILLANCE OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS DURING VACCINE TRIAL: EXPERIENCE OF CVD MALI
Doumbia, Moussa
Haidara, Fadima Cheick
Diallo, Fatoumata
Coulibaly, Flanon
Coulibaly, Adama
Tapia, Milagritos D.
Sow, Samba O.
Kotloff, Karen
Levine, Myron M.
[J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 362 - 362
[4] Serious adverse events with infliximab: Analysis of spontaneously reported adverse events
Hansen, Richard A.
Gartlehner, Gerald
Powell, Gregory E.
Sandler, Robert S.
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (06) : 729 - 735
[5] Remimazolam and serious adverse events
Kempenaers, Sander
Hansen, Tom G.
van de Velde, Marc
[J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2023, 40 (11) : 841 - 853
[6] Serious Neurological Adverse Events of Ceftriaxone
Lacroix, Clemence
Bera-Jonville, Annie-Pierre
Montastruc, Francois
Velly, Lionel
Micallef, Joelle
Guilhaumou, Romain
[J]. ANTIBIOTICS-BASEL, 2021, 10 (05):
[7] Serious adverse CV events with varenicline
[J]. Reactions Weekly, 2011, 1360 (1) : 5 - 5
[8] The International Serious Adverse Events Consortium
Arthur L. Holden
Jorge L. Contreras
Sally John
Matthew R. Nelson
[J]. Nature Reviews Drug Discovery, 2014, 13 : 795 - 796
[9] Antipsychotic serious adverse events in context
Suzuki, Takefumi
[J]. LANCET PSYCHIATRY, 2019, 6 (09): : 717 - 718
[10] Serious neurological adverse events with ivermectin
[J]. Reactions Weekly, 2018, 1692 (1) : 5 - 5

← 1 2 3 4 5 →